TV-1106
- Generic Name
- TV-1106
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02410356
- Locations
- ๐บ๐ธ
Teva Investigational Site 13166, Fountain Valley, California, United States
๐บ๐ธTeva Investigational Site 13142, Pittsburgh, Pennsylvania, United States
๐บ๐ธTeva Investigational Site 13144, Arlington, Texas, United States
Study of TV-1106 in Growth Hormone-Deficient Adults
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02410343
- Locations
- ๐ฌ๐ท
Teva Investigational Site 63054, Athens, Greece
๐ท๐บTeva Investigational Site 50303, Saint-Petersburg, Russian Federation
๐บ๐ธTeva Investigational Site 13112, Henderson, Nevada, United States
A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02092077
- Locations
- ๐ง๐พ
Teva Investigational Site 68016, Minsk, Belarus
๐ง๐ฌTeva Investigational Site 59060, Varna, Bulgaria
๐ฌ๐ชTeva Investigational Site 81022, Tbilisi, Georgia
Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency
- Conditions
- Growth Hormone Deficiency
- Interventions
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01811576
- Locations
- ๐ฌ๐ท
Teva Investigational Site 63044, Athens, Greece
๐ธ๐ฐTeva Investigational Site 62022, Bratislava, Slovakia
๐ธ๐ฎTeva Investigational Site 64016, Ljubljana, Slovenia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.